Growing doubt on COVID-19 Application, page-56

Thanks.

But I’m not sure how you say the FDA is only 20%. I would say that is 100% because it’s been a 100% blocker to date (although on other applications).

But the real problem with your analysis that if everything else is satisfactory, Novartis could sign on and progress the FDA, whatever that means, as well as everything else which needs to be progressing. To accept your position, you have to accept Novartis are happy to have everything held in limbo for 6 months and counting… during a global pandemic where stems are touted to be a miracle cure. I think this is unlikely.

More likely, Novartis didn’t think the clinical data stacks up. Or, it’s just not commercially viable because it’s too expensive and other treatments are racing ahead at warp speed (unlike MSB’s stems).